Novo Nordisk announced a strategic partnership with OpenAI on Monday to apply artificial intelligence across the pharmaceutical company’s drug development pipeline, manufacturing, and operations. Financial terms were not disclosed.
Why it matters: the deal is the latest sign that Big Pharma is moving beyond internal AI experiments and partnering directly with foundation model companies, betting that general-purpose AI can accelerate the notoriously slow drug development process.
What the partnership covers
OpenAI’s models will be deployed to analyse complex biological datasets, identify promising drug candidates, and reduce the time required to move compounds from the laboratory to clinical trials. The company said the tools would also be applied to manufacturing efficiency, supply chain management, and corporate operations.
Novo Nordisk follows Moderna and Sanofi, which have signed similar agreements with AI companies in recent months.
Workforce and governance
OpenAI will assist Novo Nordisk in upskilling its global workforce and improving AI literacy across the organisation. The partnership includes strict data protection, governance, and human oversight requirements.
Pilot programmes will launch across research, manufacturing, and commercial operations during 2026. Full integration is targeted by the end of the year.
Market reaction
Novo Nordisk’s US-listed shares rose 3% on the announcement. The company remains the dominant player in the GLP-1 obesity and diabetes market, with Ozempic and Wegovy generating tens of billions in annual revenue.
What happens next
Investors will watch for early results from the pilot programmes. The real test is whether AI can meaningfully compress development timelines for Novo Nordisk’s next-generation obesity treatments, several of which are in mid-stage clinical trials.